"A randomized, single-blind, placebo-controlled, single-center, single-dose-escalation, and multi-dose-escalation phase I trial evaluated the safety, tolerability, pharmacokinetic, and preliminary pharmacodynamic characteristics of subcutaneous RBD7022 in subjects with normal or elevated LDL cholesterol" is ongoing.

RBD 7022 is a GalNAc-conjugated siRNA against PCSK9 (proprotein convertase subtilisin/kexin type 9) for the treatment of hyperlipidemia by lowering LDL-C (low-density lipoprotein cholesterol). The drug reduces LDL-R (low-density lipoprotein receptor) lysosomal degradation and increases the number of LDL-R on the surface of liver cells, thus reducing LDL-C levels in the blood. 

In September 2022, the product received approval from the National Medical Products Administration (NMPA) to conduct its first in human clinical trial in China.

In April 2023, the study was initiated at the Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences (Peking Union Medical College), and is currently in the multi-dose incremental enrolment phase.